September 30, 2009 β A simple, noninvasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.
September 29, 2009 β Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent achieved superiority in the key safety and efficacy measures compared to the TAXUS Express Paclitaxel-Eluting Coronary Stent at one year, which will likely guarantee XIENCEβs continued domination of t
September 30, 2009 β MAQUET Cardiovascular said Johannes Bonatti, M.D., professor of surgery and director of coronary surgery and advanced coronary interventions at the University of Maryland Heart Center in Baltimore, recently completed the world's first use of the MAQUET Minimized Extra-Corporeal Circulation (MECC) system during a successful robotic and fully endoscopic heart surgery.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
September 30, 2009 β Positron Corp. predicts a significant rise in demand for cardiac PET in 2010 with a proposed cut in SPECT reimbursement of 46 percent and an increase in PET reimbursement of 22 percent, issued by the Centers for Medicare & Medicaid Services (CMS).
September 29, 2009 β Cordis Corp. and Boston Scientific announced late today they reached an agreement to resolve several pending lawsuits over intellectual property related to drug-eluting stent and balloon deliver system technologies.
September 29, 2009 β Abiomed Inc. announced new clinical data last week at TCT 2009 from Academic Medical Centerβs (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II trial, revealing improved left ventricular function, cardiac output and quality of life.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
September 29, 2009 β Volcano Corp.
September 29, 2009 β Mardil Inc. last week at TCT 2009 announced positive interim data from a pilot study investigating the safety and efficacy of its novel cardiac device β BACE (Basal Annuloplasty of the Cardia Externally) β in treating mitral valve regurgitation.
September 29, 2009 β Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter first-in-man studies of its novolimus and myolimus-eluting coronary stent systems with durable and bioabsorbable polymers. Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
September 29, 2009 β Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI trial, is designed to determine the safety and efficacy of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI).
September 29, 2009 β At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported significantly less chest pain than those receiving the TAXUS Liberte stent, and patients also reported improvements in their overall quality of life.
September 29, 2009 β The United States Court of Appeals for the Federal Circuit last week affirmed the previous ruling of the United States District Court for the Northern District of California that Cook Incorporated does not infringe on Edwardsβ patents for endovascular devices to treat aneurysms, Cook officials said.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
September 29, 2009 β GE Healthcare said the first clinical use of true integrated Fractional Flow Reserve (FFR) has been implemented at Christus St. Vincent Regional Medical Center in Santa Fe, N.M., to evaluate the severity of lesions in coronary arteries.
September 28, 2009 β New data from the phase III PLATO study showed that ticagrelor (BRILINTA) provided 16 percent reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02 vs. 10.65 percent) in acute coronary syndromes patients undergoing planned invasive treatment of either PCI or CABG.
September 28, 2009 β Sanofi-aventis announced last week the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq (dronedarone 400mg tablets).